Skip to content

EyePoint, Inc. EYPT Current ratio

Current ratio at other companies

Merck & Co. logo
Merck & Co.MRK
1.3×-0.1×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
3.6×-1.4×
Ocular Therapeutix logo
Ocular TherapeutixOCUL
14.8×+4.6×
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
3.5×-1.1×
HRO
HarrowHROW
2.5×+1.6×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-0.4×

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+189%
Enterprise value$1.15B+228%
P/S158.5×+151×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×

Where this comes from

Calculated from EyePoint, Inc. ’s reported figures.

Based on the most recent quarter.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's current ratio?
EyePoint, Inc. (EYPT) reported current ratio of 6.7× in Q1 2026.
How has EyePoint, Inc. 's current ratio changed year-over-year?
EyePoint, Inc. 's current ratio decreased by 15.1% year-over-year, from 7.8× to 6.7×.
What is the long-term trend for EyePoint, Inc. 's current ratio?
Over 5 years (2020 to 2025), EyePoint, Inc. 's current ratio has grown at a 15.9% compound annual growth rate (CAGR), from 4.2× to 8.9×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.